InnoCare Pharma Limited

SEHK:9969 Stock Report

Market Cap: HK$12.6b

InnoCare Pharma Management

Management criteria checks 3/4

InnoCare Pharma's CEO is Jasmine Cui, appointed in Aug 2016, has a tenure of 8.33 years. total yearly compensation is CN¥22.63M, comprised of 20.8% salary and 79.2% bonuses, including company stock and options. directly owns 5.73% of the company’s shares, worth HK$724.32M. The average tenure of the management team and the board of directors is 3.3 years and 9.1 years respectively.

Key information

Jasmine Cui

Chief executive officer

CN¥22.6m

Total compensation

CEO salary percentage20.8%
CEO tenure8.3yrs
CEO ownership5.7%
Management average tenure3.3yrs
Board average tenure9.1yrs

Recent management updates

Recent updates

Pinning Down InnoCare Pharma Limited's (HKG:9969) P/S Is Difficult Right Now

Dec 18
Pinning Down InnoCare Pharma Limited's (HKG:9969) P/S Is Difficult Right Now

Is InnoCare Pharma (HKG:9969) A Risky Investment?

Oct 21
Is InnoCare Pharma (HKG:9969) A Risky Investment?

Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 29%

Sep 13
Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 29%

Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report

Aug 22
Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report

Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

Jun 21
Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

Some Analysts Just Cut Their InnoCare Pharma Limited (HKG:9969) Estimates

Apr 02
Some Analysts Just Cut Their InnoCare Pharma Limited (HKG:9969) Estimates

Is InnoCare Pharma (HKG:9969) Weighed On By Its Debt Load?

Feb 14
Is InnoCare Pharma (HKG:9969) Weighed On By Its Debt Load?

Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

Oct 06
Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

Is InnoCare Pharma (HKG:9969) Using Too Much Debt?

May 11
Is InnoCare Pharma (HKG:9969) Using Too Much Debt?

Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 36% Undervaluation?

Apr 11
Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 36% Undervaluation?

Is InnoCare Pharma (HKG:9969) A Risky Investment?

Jan 25
Is InnoCare Pharma (HKG:9969) A Risky Investment?

Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt

Sep 05
Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt

InnoCare Pharma (HKG:9969) Is Using Debt Safely

Apr 30
InnoCare Pharma (HKG:9969) Is Using Debt Safely

CEO Compensation Analysis

How has Jasmine Cui's remuneration changed compared to InnoCare Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CN¥376m

Jun 30 2024n/an/a

-CN¥471m

Mar 31 2024n/an/a

-CN¥761m

Dec 31 2023CN¥23mCN¥5m

-CN¥631m

Sep 30 2023n/an/a

-CN¥584m

Jun 30 2023n/an/a

-CN¥867m

Mar 31 2023n/an/a

-CN¥781m

Dec 31 2022CN¥24mCN¥4m

-CN¥887m

Sep 30 2022n/an/a

-CN¥987m

Jun 30 2022n/an/a

-CN¥296m

Mar 31 2022n/an/a

-CN¥78m

Dec 31 2021CN¥29mCN¥3m

-CN¥65m

Sep 30 2021n/an/a

CN¥60m

Jun 30 2021n/an/a

-CN¥266m

Mar 31 2021n/an/a

-CN¥329m

Dec 31 2020CN¥120mCN¥1m

-CN¥391m

Sep 30 2020n/an/a

-CN¥2b

Jun 30 2020n/an/a

-CN¥2b

Mar 31 2020n/an/a

-CN¥2b

Dec 31 2019CN¥17mCN¥3m

-CN¥2b

Sep 30 2019n/an/a

-CN¥742m

Jun 30 2019n/an/a

-CN¥592m

Mar 31 2019n/an/a

-CN¥571m

Dec 31 2018CN¥26mCN¥2m

-CN¥550m

Compensation vs Market: Jasmine's total compensation ($USD3.10M) is above average for companies of similar size in the Hong Kong market ($USD494.85K).

Compensation vs Earnings: Jasmine's compensation has been consistent with company performance over the past year.

CEO

Jasmine Cui (61 yo)

8.3yrs

Tenure

CN¥22,626,000

Compensation

Dr. Jisong Cui, Ph.D. also known as Jasmine, has been Co-Founder InnoCare Pharma, Ltd. and serves as Chief Executive Officer of InnoCare Pharma, Ltd. since August 18, 2016 and its Chairwoman since Septembe...

Leadership Team

NamePositionTenureCompensationOwnership
Jisong Cui
Co-Founder8.3yrsCN¥22.63m5.73%
HK$ 724.3m
Renbin Zhao
VP of Clinical Development & Medical Research and Executive Directorno dataCN¥4.06m6.46%
HK$ 816.8m
Xin Fu
Chief Financial Officerless than a yearno datano data
Nan Gao
Chief Operating Officer3.4yrsno datano data
Yue Tan
Accounting Supervisorno datano datano data
Xiangyang Chen
Chief Technology Officer5.2yrsno data0.0071%
HK$ 896.6k
Junsu Wang
General Counsel3.3yrsno datano data
Davy Ouyang
VP & Head of Biology3.3yrsno datano data
Jeff Chen
Chief Commercial Officerless than a yearno datano data
Bei Yuan
Secretary of the Boardno datano datano data

3.3yrs

Average Tenure

52.5yo

Average Age

Experienced Management: 9969's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jisong Cui
Co-Founder9.1yrsCN¥22.63m5.73%
HK$ 724.3m
Renbin Zhao
VP of Clinical Development & Medical Research and Executive Director9.1yrsCN¥4.06m6.46%
HK$ 816.8m
Arnold Levine
Member of Scientific Advisory Boardno datano datano data
Yigong Shi
Non-Executive Director & President of Scientific Advisory Board9.1yrsno data0.18%
HK$ 22.2m
Zemin Zhang
Member of Scientific Advisory Board9.1yrsno datano data
Zhanguo Li
Member of Scientific Advisory Boardno datano datano data
Ronggang Xie
Non-Executive Director3.8yrsno datano data
Lan Hu
Independent Non-Executive Director4.8yrsno datano data
Dandan Dong
Independent Non-Executive Director1.2yrsno datano data

9.1yrs

Average Tenure

55.5yo

Average Age

Experienced Board: 9969's board of directors are considered experienced (9.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 17:47
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

InnoCare Pharma Limited is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peng ZouChina International Capital Corporation Limited
Tan Huan GanCitic Securities Co., Ltd.
Shitong HanCitic Securities Co., Ltd.